Literature DB >> 6721447

Effect of high-dose intravenous steroid administration on contrast-enhancing computed tomographic scan lesions in multiple sclerosis.

R Troiano, M Hafstein, M Ruderman, P Dowling, S Cook.   

Abstract

Six consecutive patients with multiple sclerosis and lesions contrast enhancing on computed tomographic scan were treated with high-dose intravenous infusions of methylprednisolone. Double-dose delayed computed tomographic scans were repeated at varying intervals during corticosteroid treatment. Contrast enhancement of sclerotic plaques was reduced or eliminated within as little as 8 hours after the first infusion. Rapid associated partial clinical improvement was noted in four patients with recent exacerbations of disease activity. Similar attenuation of contrast-enhancing plaques and clinical improvement were less predictable following oral corticosteroid therapy in conventional dosage. These studies suggest that the dose, route of administration, and duration of corticosteroid therapy in multiple sclerosis may partially determine the effect of treatment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721447     DOI: 10.1002/ana.410150309

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  12 in total

1.  Short-term neurophysiological monitoring in multiple sclerosis bouts. Evaluation of steroid treatment.

Authors:  V Scaioli; C Milanese; A Salmaggi; L LaMantia; A Campi; M Eoli; F Panzica
Journal:  Ital J Neurol Sci       Date:  1992-03

2.  Immunological treatment of multiple sclerosis. II.

Authors:  R A Hughes
Journal:  J Neurol       Date:  1986-04       Impact factor: 4.849

3.  Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone.

Authors:  J Kesselring; D H Miller; D G MacManus; G Johnson; N M Milligan; N Scolding; D A Compston; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-01       Impact factor: 10.154

4.  Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis.

Authors:  B N McLean; A Z Zeman; D Barnes; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

Review 5.  Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis.

Authors:  D E Goodkin
Journal:  West J Med       Date:  1994-09

6.  High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect.

Authors:  D H Miller; A J Thompson; S P Morrissey; D G MacManus; S G Moore; B E Kendall; I F Moseley; W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-06       Impact factor: 10.154

7.  Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis.

Authors:  F Barkhof; M W Tas; S T Frequin; P Scheltens; O R Hommes; J J Nauta; J Valk
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

8.  Relationship of nuclear magnetic resonance examinations to clinical data, cerebrospinal fluid findings and visual evoked potentials in multiple sclerosis.

Authors:  D Uhlenbrock; E Herbe; M Haupts
Journal:  Neurosurg Rev       Date:  1987       Impact factor: 3.042

Review 9.  Anoxic asphyxia--a cause of industrial fatalities: a review.

Authors:  P B James; I M Calder
Journal:  J R Soc Med       Date:  1991-08       Impact factor: 18.000

10.  Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis.

Authors:  Friedemann Paul; Sonia Waiczies; Jens Wuerfel; Judith Bellmann-Strobl; Jan Dörr; Helmar Waiczies; Mareile Haertle; Klaus D Wernecke; Hans-Dieter Volk; Orhan Aktas; Frauke Zipp
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.